La cadena de opciones muestra datos clave de las opciones de acciones de IMAC Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para IMAC Holdings..

IMAC Holdings (OTC:BACK) Bolsa, Cadena de Opciones

IMAC Hldgs

IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

IMAC Holdings Inc

Backblaze Inc

Backstageplay Inc

JMP Securities analyst Mitch Germain reiterates Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) from Market Perform to Market Perform.

News

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Perform on Agree Realtyto Market Perform

APDN

Applied DNA Conducts 27% Workforce Reduction And Ceases Operations At Applied DNA Clinical Lab; will focus Exclusively On LineaRx Business

The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients
Windtree has previously reported two positive early cardiogenic shock Phase 2 studies in SCAI Stage B patients
The SEISMiC C interim analysis will provide a preliminary assessment of istaroxime safety in treating more severe cardiogenic shock patients who may be receiving standard of care with inotropes and vasopressors
SCAI Stage C is a sicker patient population than early cardiogenic shock and has high mortality despite currently used drug treatments
WARRINGTON, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the Company has reached the planned enrollment of 20 patients for the interim analysis in its istaroxime Phase 2 SEISMiC C study in SCAI Stage C cardiogenic shock patients.

WINT

Windtree Therapeutics Reaches Planned Enrollment Of 20 Patients For Interim Analysis In Istaroxime Phase 2 SEISMiC C Study In SCAI Stage C Cardiogenic Shock Patients

Parker Hannifin To Acquire Curtis Instruments For ~$1B In Cash; Curtis Expects Calendar Year 2025 Sales Of ~$320M

Vail Resorts, Inc. (NYSE:&nbsp;MTN) today announced it intends to commence a private offering to eligible purchasers, subject to market and other conditions, of $400 million in aggregate principal amount of senior notes due 2030 (the "Notes"). The Notes will be unsecured senior obligations of the Company and will be guaranteed by certain of the Company's domestic subsidiaries (other than certain excluded subsidiaries).
The Company intends to use the proceeds from the proposed offering to repay borrowings under its revolving credit facility incurred to fund the repurchase of $200 million of its outstanding shares of common stock completed in June 2025 and the repurchase or repayment of a portion of its outstanding 0.00% Convertible Senior Notes due 2026 at or prior to their maturity on January 1, 2026, and, in each case, to pay related fees and expenses. This press release does not constitute an offer to repurchase the Company's outstanding 0.00% Convertible Senior Notes due 2026.

Vail Resorts Intends To Commence Private Offering Of $400M In Aggregate Principal Amount Of Senior Notes Due 2030

Across the recent three months, 15 analysts have shared their insights on ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ARM Holdings and provided 12-month price targets. The average target is $152.2, accompanied by a high estimate of $187.00 and a low estimate of $115.00. Highlighting a 12.99% decrease, the current average has fallen from the previous average price target of $174.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1751288463_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of ARM Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$187.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Ananda Baruah</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Gardiner</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$135.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$147.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$144.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ARM Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ARM Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ARM Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ARM Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind ARM Holdings</h2>
Arm Holdings is the IP owner and developer of the ARM architecture, which is used in 99% of the world's smartphone CPU cores, and it also has high market share in other battery-powered devices like wearables, tablets, or sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allow them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Both off-the-shelf and architectural customers pay a royalty fee per chip shipped.
<h3>Unraveling the Financial Story of ARM Holdings</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: ARM Holdings displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 33.73%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: ARM Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.92%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ARM Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.17%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): ARM Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.41% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.05, ARM Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About ARM Holdings Stock

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) with a Buy and raises the price target from $88 to $115.

Price Target

Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $115

Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $8.62, a high estimate of $13.00, and a low estimate of $5.00. This current average has decreased by 27.26% from the previous average price target of $11.85. 
<img src="https://www.benzinga.com/files/images/story/2025/1751288436_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Neogen among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$6.40</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.50</td>
<td>$13.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Neogen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Neogen compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Neogen's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Neogen's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NEOG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neogen analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Neogen's Background</h2>
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.
<h3>Neogen's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Neogen's revenue growth over a period of 3M has faced challenges. As of 28 February, 2025, the company experienced a revenue decline of approximately -3.42%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Neogen's net margin excels beyond industry benchmarks, reaching -4.96%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Neogen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.41% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Neogen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.27% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NEOG

What 4 Analyst Ratings Have To Say About Neogen

Cipher Mining's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NYSE">CIFR</a>) short percent of float has risen 6.67% since its last report. The company recently reported that it has 44.75 million shares sold short, which is 17.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cipher Mining Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751288431_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cipher Mining has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cipher Mining's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cipher Mining's peer group average for short interest as a percentage of float is 9.65%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

CIFR

Is Cipher Mining Gaining or Losing Market Support?

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $97.5, along with a high estimate of $110.00 and a low estimate of $90.00. This upward trend is evident, with the current average reflecting a 0.93% increase from the previous average price target of $96.60.
<img src="https://www.benzinga.com/files/images/story/2025/1751288428_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Medtronic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Medtronic. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Medtronic's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Medtronic's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>About Medtronic</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
<h3>Understanding the Numbers: Medtronic's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Medtronic's remarkable performance in 3M is evident. As of 30 April, 2025, the company achieved an impressive revenue growth rate of 3.94%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Medtronic's net margin is impressive, surpassing industry averages. With a net margin of 11.83%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE stands out, surpassing industry averages. With an impressive ROE of 2.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Medtronic's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.16% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.59, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Medtronic Stock

IES Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NYSE">IESC</a>) short percent of float has risen 29.38% since its last report. The company recently reported that it has 988 thousand shares sold short, which is 11.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>IES Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751288426_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for IES Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing IES Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, IES Hldgs's peer group average for short interest as a percentage of float is 5.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

IESC

Is the Market Bullish or Bearish on IES Hldgs?

Vistra's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) short percent of float has fallen 8.13% since its last report. The company recently reported that it has 6.60 million shares sold short, which is 2.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Vistra Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751288422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vistra has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Vistra's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Vistra's peer group average for short interest as a percentage of float is 4.15%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Vistra?

AIMDW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Beneath the surface of the AI frenzy, a high-stakes struggle is unfolding, as tech giants in Silicon Valley engage in a fierce battle for supremacy and one New York publisher is caught up in the mix.&nbsp;
<h2 class="wp-block-heading">A Tale of Two American Coasts</h2>
At the epicenter of this conflict lies a landmark lawsuit that could redefine the trajectory of AI: The New York Times has launched a legal challenge against OpenAI, sending shockwaves through the industry. This high-profile showdown not only highlights the cutthroat competition in the AI sector but also raises fundamental concerns regarding user data protection and the unbridled proliferation of AI technologies.
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="767" height="453" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/28002151/AI-Bourque-NYT.jpg" alt="" class="wp-image-15041" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/28002151/AI-Bourque-NYT.jpg 767w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/28002151/AI-Bourque-NYT-300x177.jpg 300w" sizes="(max-width: 767px) 100vw, 767px" /><figcaption class="wp-element-caption">Source: AI-Generated by Andre Bourque</figcaption></figure>
The lawsuit between The New York Times and OpenAI is more than just a legal tussle; it serves as a harbinger for the AI industry&#8217;s future prospects. The lawsuit, which alleges unauthorized use of copyrighted content for AI training purposes, has brought to the forefront critical questions about intellectual property rights in the digital age. At its core, the dispute centers on OpenAI&#8217;s practice of using vast amounts of published content, including Times articles, to train its sophisticated language models without obtaining explicit permission or providing compensation.
OpenAI's success has largely been built on its ability to train these systems using enormous datasets of text from across the internet. However, this practice has now come under intense scrutiny, as content creators and publishers begin to question the legality and ethics of using their intellectual property for AI training purposes. The implications of this legal battle extend far beyond the immediate parties involved.&nbsp;
The outcome of this case could reshape the landscape of AI development and content licensing, which is ultimately what publishers want. If successful, the Times&#8217; lawsuit might lead to the establishment of new licensing frameworks for AI training data, potentially increasing development costs but also creating new revenue streams for content creators. It might also prompt AI companies to be more selective in their data collection practices and more proactive in securing permissions from content owners.
<h2 class="wp-block-heading">The Promise for the Publishing Industry</h2>
For the publishing industry, this lawsuit represents a crucial stand against what many view as the unauthorized exploitation of their valuable content. Publishers argue that the systematic use of their articles for AI training threatens their business models and devalues their intellectual property. They contend that if AI companies profit from using their content, they should be fairly compensated for this use.
Why not, right? After all, it's their content.&nbsp;
That said, the The New York Times isn't waiting around for this legal case to be resolved before pursuing the content licensing arrangements they desire. Just last month, the publisher <a href="https://digiday.com/media/amazon-and-the-new-york-times-ai-deal-signals-a-new-wave-of-publisher-partnerships/">signed a licensing agreement with Amazon</a>. The agreement will allow Amazon products to use summaries and short excerpts from NYT stories and recipes, as well as to incorporate this content in the training of its proprietary AI models.
"We're open to being at the table, if you're willing to come to the table," one former NYT executive said on condition of anonymity. "Until [this] announcement, they've been sort of hiding in the shadows. Now they're saying, ‘we're open for business under the right terms and conditions.'&#8221;
<h2 class="wp-block-heading">Data Protection Implications</h2>
The New York Times lawsuit against OpenAI indirectly underscores these data protection concerns, highlighting the need for greater scrutiny and regulation. As AI models become increasingly ubiquitous, the data they are trained on and the interactions they have with users will be subject to intense scrutiny. Regulators are beginning to take notice, and we can expect a wave of new regulations aimed at safeguarding user data in the context of AI.
If The New York Times emerges victorious, it could establish a precedent that necessitates AI developers to secure permission and potentially pay for the data used to train their models. This, in turn, could lead to increased costs associated with developing AI, potentially limiting the availability of high-quality training data. As a result, OpenAI and other AI developers may need to reassess their data acquisition strategies, which could lead to a slowdown in AI development or a shift towards alternative, potentially less effective, data sources.
Furthermore, this lawsuit touches on the broader issue of intellectual property rights in the age of AI, where the lines between data ownership and usage are becoming increasingly blurred. As AI models become increasingly sophisticated, they rely on vast amounts of data, a significant portion of which is copyrighted or owned by third-party entities, including individual creators. The outcome of this case could significantly influence how AI companies approach data usage, potentially leading to a more regulated and transparent AI development process.
The AI war is also being fought on the battleground of user data protection, where concerns over data collection, usage, and security are reaching a fever pitch. AI models like ChatGPT and others have raised red flags regarding their potential to compromise user privacy, as they not only ingest vast amounts of data but also interact with users, generating responses that can sometimes reveal sensitive information. The implications for user data protection are significant, as AI systems can inadvertently expose personal data or be exploited by malicious actors to elicit sensitive information from users.
<h2 class="wp-block-heading">AI Investor Considerations</h2>
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="1024" height="550" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/28060430/image-29985947234-550.jpg" alt="" class="wp-image-15046" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/28060430/image-29985947234-550.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/28060430/image-29985947234-550-300x161.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/28060430/image-29985947234-550-768x413.jpg 768w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Source: AI-Generated by Andre Bourque</figcaption></figure>
For investors in the AI space, the current landscape presents a complex mix of opportunities and challenges. On one hand, the potential for growth in the AI sector is vast, with applications <a href="https://www.benzinga.com/general/health-care/25/06/46140911/healthcare-ai-draws-major-funding-bucking-market-uncertainty">spanning industries from healthcare and finance</a> to education and entertainment. On the other hand, the risks associated with AI development, including regulatory risks, data protection concerns, and the potential for market saturation, must be carefully navigated.
As the AI content rights war continues to unfold, investors would do well to keep a close eye on developments like the New York Times vs. OpenAI lawsuit, which will likely shape the future of AI. The outcome of this case, coupled with the evolving regulatory landscape and the competitive dynamics of Silicon Valley&#8217;s AI titans, will be crucial in determining the trajectory of AI, with far-reaching implications for the future of technology.&nbsp;
As AI continues to reshape the world, understanding these dynamics will be crucial for investors, policymakers, and anyone concerned about the future of technology. The New York Times suing OpenAI is just the beginning, a sign of the complex and challenging road ahead as we navigate the uncharted territories of AI.
Feature Image: AI-Generated by Andre Bourque

Legal

Opinion

General

East Vs. West: The AI Data Battle Between Publishers And LLMs

Guggenheim analyst Subbu Nambi maintains Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) with a Buy and raises the price target from $65 to $75.

Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $75

A historic inflow streak into the world&#8217;s biggest exchange traded fund has come to a sudden end in June, with the S&amp;P 500 benchmark fund losing billions even as Wall Street <a href="https://www.benzinga.com/markets/equities/25/06/46163999/us-stocks-likely-to-open-higher-continuing-record-setting-advances-june-has-never-seen-an-all-time-high-since-1950-highlights-expert">celebrated fresh record highs. </a>
The Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) saw $5.69 billion in outflows during the month, marking its first monthly net redemption since December 2022 and the second-largest outflow since the fund's launch in 2015.
The redemptions signal a notable divergence between market performance and investor behavior. The S&amp;P 500 reached new all-time highs in late June, yet large swaths of institutional and retail investors opted to take profits and reduce exposure.
Over the three years leading up to June 2025, the VOO ETF attracted $250 billion in inflows, overtaking the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) to become the world's largest ETF.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30083412/image-437-1024x528.png" alt="" class="wp-image-966892" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30083412/image-437-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30083412/image-437-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30083412/image-437-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30083412/image-437-1536x792.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30083412/image-437-2048x1056.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Broad-Based Redemptions Across Some Large-Cap ETFs</h3>
The outflows from Vanguard's S&amp;P 500 ETF were far from an isolated case, as other major large-cap funds also saw significant investor withdrawals.
The Invesco Equal-Weight S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSP#NYSE">RSP</a>) shed $1.6 billion in June, marking its steepest monthly outflow since March 2020. 
Meanwhile, the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) posted $1.7 billion in redemptions, its largest since December 2020. 
Even the Roundhill Magnificent Seven ETF (CBOE: MAGS), a relatively new fund focused on mega-cap tech names, saw $102 million in outflows—only the second monthly decline in assets since its debut in November 2023.
<h3 class="wp-block-heading">Why Are Investors Pulling Back Amid Record Highs?</h3>
Veteran Market strategist Ed Yardeni said investor sentiment remains cautious, despite easing geopolitical concerns and progress on trade policy under President Donald Trump.
"Though the stock market is back on record-high ground after a couple of big worries have dissipated, investors remain wary, sentiment readings show," Yardeni said in a note on Monday.
Yardeni highlighted the ceasefire in the 12-day conflict between Israel and Iran and improved outlooks regarding Trump&#8217;s proposed trade policies, yet noted that traditional sentiment indicators like the AAII Bull-Bear Ratio and Investor Intelligence surveys remain subdued.
"Stock investors always find something to worry about," Yardeni said. 
In Yardeni's view, the disconnect between price action and sentiment could suggest that a large portion of the current rally is being driven by passive or algorithmic flows, rather than broad-based investor enthusiasm. 
<h3 class="wp-block-heading">Technical Strength vs. Macro Uncertainty</h3>
On the technical front, Adam Turnquist, chief technical strategist at LPL Financial, recently indicated that historical patterns suggest momentum tends to continue after a market reaches new highs.
According to Turnquist&#8217;s analysis, after reaching new highs, the S&amp;P 500 posted average and median 12-month returns of 9.7% and 8.6%, respectively. Notably, 74% of those occurrences led to positive performance over the following year.
Still, Turnquist flagged macro risks that could limit further gains.
 "A lot of good news is arguably priced into the market," he said.
Further upside in equities, Turnquist added, will likely hinge on several variables aligning: upside earnings surprises, lower-than-expected tariff levels, passage of Trump's "Big Beautiful Bill" with limited market disruptions, and ideally, a moderation in interest rates on the longer end of the yield curve.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46166058/elon-musk-birthday-trump-tax-bill-economy">Elon Musk&#8217;s Birthday Wish: Kill The Bill Before It Kills The Economy</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

SPDR Dow Jones Industrial Average ETF Trust

MAGS

Rydex ETF Trust Rydex S&P Equal Weight ETF

This S&P 500 ETF Saw A 30-Month Buying Spree — Now It's Over

Guggenheim analyst Subbu Nambi maintains Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Buy and lowers the price target from $13 to $10.

Guggenheim Maintains Buy on Neogen, Lowers Price Target to $10

Momentus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares are rocketing higher Monday morning after the company announced <a href="https://www.benzinga.com/pressreleases/25/06/b46165964/momentus-awarded-nasa-contract-for-in-space-power-system-demonstration">multiple contract wins</a>. 
What Happened: Momentus was awarded a contract by NASA to demonstrate a power processing unit for Hall Thrusters based upon CisLunar Industries&#8217; modular configurable electric power converter technologies. The unit is designed to help advance in-space assembly operations.
Under the contract, managed by NASA&#8217;s Flight Opportunities program, Momentus will host one of CisLunar Industries&#8217; payloads to conduct in-orbit testing&nbsp;of power processing unit technology. The company will carry the payload alongside other payloads on its Vigoride 7 orbital service vehicle scheduled for launch no earlier than February 2026.
Separately, Momentus <a href="https://www.benzinga.com/pressreleases/25/06/b46165956/momentus-wins-contract-in-highly-competitive-u-s-space-force-spacewerx-sustained-space-maneuver-ch">announced</a> that it signed a&nbsp;$1.86 million contract with the U.S. Air Force&#8217;s innovation arm SpaceWERX. The company will work to complete an in-space flight demonstration of a multi-spectral sensor suite scheduled for early 2026.
Momentus said the demonstration involves an internally developed system equipped with optical, infrared and lidar&nbsp;(light detection and ranging) sensors.&nbsp;
&#8220;This contract marks a major milestone in advancing cost-effective, autonomous in-space operations,&#8221; said&nbsp;John Rood, CEO of Momentus. 
&#8220;We&#8217;re honored to support the U.S. Space Force and Department of the Air Force in developing the advanced capabilities needed to support their plans for dynamic space operations such as orbital servicing and refueling of satellites, assembly of structures in space, and debris mitigation.&#8221;
Momentus shares are likely to be highly volatile given that it had a market cap of just $8.85 million as of Friday&#8217;s close. Momentus has a total float of about 6.27 million shares and has short interest of around 7%, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
MNTS Price Action: <a href="http://benzinga.com/quote/mnts">Momentus shares</a> are down approximately 82% year-to-date. The space stock was up 24.8% at $1.75 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/space/25/06/46135182/elon-musks-spacex-says-starship-debris-recovery-hindered-by-trespassing-unauthorized-parties-seeks-help-from-mexican-authorities">Elon Musk&#8217;s SpaceX Says Starship Debris Recovery Hindered By Trespassing &#8216;Unauthorized Parties,&#8217; Seeks Help From Mexican Authorities</a></li>
</ul>
Photo: Shutterstock.

SPACE

Movers

MNTS

Momentus Stock Rockets Higher Following Multiple Contract Wins

BGFV

Trading Halt: Halt status updated at 8:55:01 AM ET: Quotation Resumption: News and Resumption Times

AIMD

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Press Releases

IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology

IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)

IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies

Stocks Under $2 to Watch in February 2025: TRIB, MODD, PNPN.V, BACK – More Inside!

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

Comments

IMAC Holdings

IMAC Holdings (BACK) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL